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There are many dimensions in the strug-
gle to provide better care for patients with 
ischemic stroke including patient educa-
tion, logistic organization both before and 
during hospitalization, economic, and legal 
issues, as well as the continuing quest for 
more effective therapies.
For  years,  the  management  of  acute 
ischemic stroke, has been a source of frustra-
tion and dismay for physicians, families, and 
even patients alike, as effective treatment to 
reverse a neurologic deficit was lacking.
Now, despite the availability of thrombo-
lytic therapy that leads to better outcomes, 
the exasperation continues as the percent-
age  of  patients  receiving  such  treatment 
languishes in the single digits.
Cornerstone  to  the  improvement  of 
stroke therapy is the development of guide-
lines and education of physicians involved 
in the treatment of these patients. But edu-
cation is not enough as some neurologists 
have chosen not to participate in the care 
of stroke patients, which makes clear that if 
neurology wishes to retain acute stroke care 
as part of their “turf,” those willing to care 
for these patients within the specialty must 
be knowledgeable about current best treat-
ment and be part of a peer review system to 
monitor the care delivered.
These steps are important considering 
that at the base of effective stroke manage-
ment is its prompt and accurate recognition. 
But what lead the need of rapid recogni-
tion and treatment was the understanding 
of  the  pathophysiological  phenomenon 
called ischemic penumbra which provided 
the medical community with a lucid expla-
nation  of  acute  ischemic  stroke  and  the 
rationale of the treatment. In addition, it 
had driven home the message that for many 
stroke patients salvation of critical brain tis-
sues is possible.
One  would  imagine  that  with  these 
fundamentals we are better equipped to 
tackle the dark cave of acute stroke man-
agement. However the situation is more 
complicated considering that regardless 
of how accurate or rapid the diagnosis is 
made, the definite imaging diagnosis of 
penumbra is still a source of controversy as 
I will explain. For years and in absence of 
a better marker for potentially salvageable 
tissue, Time is brain has been an appro-
priate mantra for the prompt delivery of 
stroke care, and the earlier articles and 
works emphasized its importance. But like 
the “Carrier pigeon” it has become, in my 
opinion, a myth that should be replaced 
by Physiology is brain, as imaging tech-
nology can potentially free us from the 
time constrains by objectively demarcat-
ing the penumbra regardless of the time 
frame and therefore unleashing this hid-
den dimension that can help expand the 
benefit of thrombolysis to a wider acute 
stroke patients population. Considerable 
efforts have been made to squeeze more of 
the now ancient concept of Time is brain 
trying to expand the benefit in favor of 
stroke patients. In a study by Rudd et al. 
(2010), they could show from observa-
tional data extracted from the National 
Sentinel Stroke 2008 Audit, that thrombo-
lytic rates are low in the United Kingdom. 
Fourteen percent of patients were poten-
tially suitable for thrombolysis using the 
3-h time window.
The number increased only marginally if 
the window was extended to include those 
up to 4.5 h. There is no doubt that the big-
gest impact on increasing the proportion of 
patients suitable for thrombolysis would be 
by increasing the number of patients pre-
senting early and by demonstrating that the 
treatment is safe and effective in patients 
over 80 years.
Contemporary  effective  stroke  care  is 
complex, and its optimization requires the 
cooperation and efforts of many individuals 
with different training and skills, this must 
be emphasized as a crucial factor. Efforts 
paid  in  this  direction  should  be  more 
encouraged when we speak “time is Brain” 
language to purify the current guidelines 
from some beliefs that actually hinder the 
benefit  of  thrombolysis  from  reaching  a 
wide population of patients. On the other 
hand, the reading coming from similar stud-
ies should not hinder the efforts invested in 
developing technology of imaging the brain 
physiology; the main core of “Physiology is 
brain” language.
Imaging  holds  the  key  for  further 
development  despite  some  limitations. 
Perfusion/diffusion  mismatch  can  pro-
vide a working estimate of the ischemic 
penumbra in hyperacute stroke and has 
been successfully used to triage patients. 
Physiology is brain can expand the thera-
peutic window for thrombolytic therapy. 
When  large  CT-based  clinical  trials 
(The National Institute of Neurological 
Disorders and Stroke rtPA Stroke Study 
Group, 1995; The NINDS and t-PA Stroke 
Study Group, 1997; Hacke et al., 2004) 
failed to prove the benefits of intrave-
nous tissue plasminogen activator (tPA) 
administration in ischemic stroke patients 
beyond 3 h of the onset, the concept of 
PWI/DWI mismatch emerged which is 
the  volume  difference  between  a  PWI 
lesion  and  DWI  lesion  on  MRI  scans. 
It was proposed to facilitate the selec-
tion of patients with a salvageable area 
as PWI/DWI mismatch is considered to 
represent the tissue that is not irrevers-
ibly  injured  and  can  respond  to  early 
reperfusion therapy. In order to clarify 
the  clinical  significance  of  PWI/DWI 
mismatch in the selection of candidates 
for tPA therapy, some multicenter trials 
were performed. Results of desmoteplase 
in  acute  ischemic  stroke  (DIAS),  dose 
escalation  of  desmoteplase  for  acute 
ischemic  stroke  (DEDAS),  DIAS-2  did 
not  definitely  demonstrate  the  clinical 
benefits of desmoteplase administration 
in  patients  with  PWI/DWI  mismatch 
between 3 and 9 h of onset; moreover, 
DIAS-2 could not prove any effect of the 
drug. However, many lacuna of the study 
were revealed that explain these shock-
ing results and were considered enough 
rationale for the dawning of the DIAS-3 
trial.  Diffusion  and  perfusion  imag-
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25 of 97 patients (26%), the presump-
tive treatment plan was changed after 
MRI evaluation. Thirteen patients had 
their  treatment  changed  from  throm-
bolytic  to  non-thrombolytic  therapy. 
Three  patients  were  changed  from 
non-thrombolytic to intra-arterial (IA) 
thrombolysis. In one patient, treatment 
was changed from intravenous (IV) to IA 
thrombolysis, and in five patients it was 
changed from IA to IV thrombolysis. In 
two patients, systemic heparin was added 
to  antiplatelet  therapy  (Heidenreich 
et  al.,  2008;  Kakuda  and  Abo,  2008). 
So,  the  utility  of  MRI,  shown  here  to 
improve patient stratification into best-
treatment  options,  demonstrates  the 
value of using MRI to optimize care in 
hyperacute stroke patients.
Yet, no matter what we do, many patients 
will fail to reach the hospital within the 
short timeframe currently recommended 
for  administration  of  IV  thrombolytic 
therapy. This leaves the medical commu-
nity perplexed to search for the other hid-
den angle that could complete the picture. 
Till all hidden dimensions for the picture 
are  discovered  the  battle  will  continue 
  without clemency.
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evolution (DEFUSE), in which tPA was 
administered to all participants between 
3 and 6 h of stroke onset, showed that the 
occurrence of early reperfusion led to a 
favorable clinical response in patients with 
PWI/DWI  mismatch.  In  contrast,  early 
reperfusion was not beneficial in patients 
without PWI/DWI mismatch. In echopla-
nar imaging thrombolysis evaluation trial 
(EPITHET), stroke patients who showed 
PWI/DWI mismatch between 3 and 6 h of 
the onset were assigned to receive either 
alteplase or placebo. Lesion growth was 
lesser in patients with alteplase than in 
those who received placebo, although the 
difference was not statistically significant 
because of a small number of participants 
(Heidenreich  et  al.,  2008;  Kakuda  and 
Abo, 2008). Although these results sup-
ported the importance of the PWI/DWI 
concept, there still remain some issues to 
be resolved. Regarding the definition of 
PWI/ DWI mismatch, a larger mismatch 
ratio than the one that has been typically 
used seems to be recommended.
The application of MRI-based deci-
sion making strategy for stroke patients 
may facilitate the assessment and treat-
ment of stroke patients beyond 3 h of 
stroke onset, and is expected to allow 
the use of tPA for a substantially greater 
number  of  patients.  In  retrospectively 
analyzed  study,  conducted  upon  97 
patients.  In  20  of  97  patients  (21%), 
the  diagnosis  changed  after  MRI.  In 